Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock is a Buy.

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors

July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar steps into the role succeeding Lars Fruergaard Jorgensen, effective Aug. 7, 2025, which will also serve as Joregensens last day.

Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut its full year outlook for the second time in 2025, sending its shares tumbling.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.